Cancer Family
Carcinoma
CI-CAN-00000114Explore in graph →
7,369 active trials118 approved drugs1,149 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000114Explore in graph →
Clinical trials
25,729 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3,405)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03576417 | A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck(NIVOPOSTOP) | active not recruiting | Phase 3 | 680 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT04068103 | Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery | active not recruiting | Phase 2 / Phase 3 | 635 | NRG OncologyOTHER | 3 | May 7, 2025 |
| clinicaltrials |
| NCT06961201 | Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase | not yet recruiting | Phase 3 | 94 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 7, 2025 | clinicaltrials |
| NCT06028737 | Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer(OCTASUR) | recruiting | Phase 2 / Phase 3 | 150 | Ukrainian Society of Clinical OncologyOTHER | 2 | May 6, 2025 | clinicaltrials |
| NCT06955325 | Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations(UPLIFT) | not yet recruiting | Phase 3 | 270 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 0 | May 6, 2025 | clinicaltrials |
| NCT06958627 | The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study(any) | recruiting | Phase 2 / Phase 3 | 964 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT05201404 | Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis(LIVERATION) | recruiting | Phase 3 | 471 | Can-Fite BioPharmaINDUSTRY | 9 | Apr 29, 2025 | clinicaltrials |
| NCT06944496 | A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | not yet recruiting | Phase 3 | 616 | RemeGen Co., Ltd.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT05342194 | Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study | recruiting | Phase 3 | 480 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT06912698 | Reduced Dose Radiotherapy vs Standard Dose Radiotherapy for Early Stage Nasopharyngeal Carcinoma | recruiting | Phase 3 | 342 | Hai-Qiang Mai,MD,PhDOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT03592472 | A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) | recruiting | Phase 3 | 413 | Xynomic Pharmaceuticals, Inc.INDUSTRY | 6 | Apr 13, 2025 | clinicaltrials |
| NCT04974398 | A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma | active not recruiting | Phase 3 | 296 | AkesoINDUSTRY | 5 | Apr 13, 2025 | clinicaltrials |
| NCT06196736 | A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer | recruiting | Phase 3 | 432 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Apr 13, 2025 | clinicaltrials |
| NCT06926543 | Postoperative Radiotherapy in Breast Cancer- Concurrent or Sequential With Chemotherapy(CONCERT) | recruiting | Phase 3 | 858 | Dr. Tabassum WadasadawalaOTHER | 1 | Apr 13, 2025 | clinicaltrials |
| NCT06355427 | The Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma(FAPIChol) | recruiting | Phase 2 / Phase 3 | 81 | Mara Veenstra, MDOTHER | 1 | Apr 11, 2025 | clinicaltrials |
| NCT06752239 | Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in NPC(PROTECT-NPC) | recruiting | Phase 3 | 474 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT01785420 | Pre Operative Trastuzumab in Operable Breast Cancer | recruiting | Phase 3 | 1,100 | Dr Rajendra A. BadweOTHER_GOV | 1 | Apr 9, 2025 | clinicaltrials |
| NCT03168880 | A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast Cancer(TNBC) | active not recruiting | Phase 3 | 720 | Tata Memorial HospitalOTHER_GOV | 1 | Apr 9, 2025 | clinicaltrials |
| NCT03903835 | ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer(ProBio) | recruiting | Phase 3 | 750 | Karolinska InstitutetOTHER | 4 | Apr 9, 2025 | clinicaltrials |
| NCT06829459 | A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs | recruiting | Phase 3 | 350 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Apr 8, 2025 | clinicaltrials |
| NCT06911086 | SH-LPS System in Preoperative Planning for Liver Resection | not yet recruiting | Phase 2 / Phase 3 | 100 | Zhejiang Cancer HospitalOTHER | 0 | Apr 4, 2025 | clinicaltrials |
| NCT06493552 | Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors | recruiting | Phase 2 / Phase 3 | 700 | Vasgene Therapeutics, IncINDUSTRY | 1 | Apr 3, 2025 | clinicaltrials |
| NCT04711109 | Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation(BRCA-P) | active not recruiting | Phase 3 | 300 | Alliance for Clinical Trials in OncologyOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT06900218 | PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma | not yet recruiting | Phase 3 | 664 | Sun Yat-sen UniversityOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT06907602 | Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma(ONTRESCC) | recruiting | Phase 2 / Phase 3 | 120 | Peking Union Medical College HospitalOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT05255302 | De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction(DIAL) | recruiting | Phase 2 / Phase 3 | 1,360 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT02170090 | Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer(ACTICCA-1) | active not recruiting | Phase 3 | 789 | Universitätsklinikum Hamburg-EppendorfOTHER | 8 | Mar 30, 2025 | clinicaltrials |
| NCT06899477 | Pre-Operative Treatment in REseCTable COlon CanceR | not yet recruiting | Phase 3 | 714 | Dominik Paul ModestOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT04296175 | Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)(CITRINE) | active not recruiting | Phase 3 | 808 | Fudan UniversityOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT03671044 | A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients | recruiting | Phase 3 | 657 | Jina Pharmaceuticals Inc.INDUSTRY | 2 | Mar 21, 2025 | clinicaltrials |
| NCT05304468 | Reduced-dose Versus Standard Dose Radiotherapy for Nasopharyngeal Carcinomain | active not recruiting | Phase 3 | 452 | Sun Yat-sen UniversityOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06095154 | CTV Delineation Based Solely on Geometric Expansion From GTV in Nasopharyngeal Carcinoma | recruiting | Phase 3 | 474 | Fujian Cancer HospitalOTHER_GOV | 1 | Mar 13, 2025 | clinicaltrials |
| NCT05489289 | A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection | recruiting | Phase 3 | 570 | AkesoINDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06617416 | A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC | recruiting | Phase 3 | 560 | AkesoINDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT03895359 | Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma(TACE) | recruiting | Phase 3 | 128 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT06861777 | Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC | not yet recruiting | Phase 2 / Phase 3 | 474 | YIN LIOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT06867562 | Paclitaxel Lipid Suspension for Patients with Platinum-Resistant /Refractory Ovarian Cancer | not yet recruiting | Phase 3 | 166 | Jina Pharmaceuticals Inc.INDUSTRY | 0 | Mar 10, 2025 | clinicaltrials |
| NCT04460352 | Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer(NEEDS) | recruiting | Phase 3 | 1,020 | Karolinska University HospitalOTHER | 5 | Mar 6, 2025 | clinicaltrials |
| NCT06858410 | Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma | not yet recruiting | Phase 3 | 36 | Guangdong Association of Clinical TrialsOTHER | 0 | Mar 5, 2025 | clinicaltrials |
| NCT06847334 | A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX17 Vs. Keytruda® in the First-Line Treatment of Advanced Non-squamous Non-small Cell Lung Cancer | not yet recruiting | Phase 3 | 772 | Shanghai Henlius BiotechINDUSTRY | 0 | Feb 26, 2025 | clinicaltrials |
| NCT06841185 | A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma | not yet recruiting | Phase 3 | 656 | Shanghai Henlius BiotechINDUSTRY | 0 | Feb 24, 2025 | clinicaltrials |
| NCT05955924 | Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial(SPRINTR) | recruiting | Phase 3 | 396 | Women's College HospitalOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT04344158 | A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) | active not recruiting | Phase 3 | 648 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Feb 20, 2025 | clinicaltrials |
| NCT06696794 | Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients | recruiting | Phase 3 | 180 | Shaogang WangOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06828757 | Clinical Study of Nanocrystalline Megestrol in Malnourished Patients With First-Line Non-Small Cell Lung Cancer | not yet recruiting | Phase 3 | 94 | Hunan Province Tumor HospitalOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT05737303 | Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer | recruiting | Phase 3 | 538 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT06789796 | a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy. | not yet recruiting | Phase 3 | 636 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Feb 11, 2025 | clinicaltrials |
| NCT02859038 | Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY) | active not recruiting | Phase 3 | 489 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 2 | Feb 10, 2025 | clinicaltrials |
| NCT06782412 | Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types(FAPIDO) | recruiting | Phase 2 / Phase 3 | 109 | KU LeuvenOTHER | 1 | Feb 7, 2025 | clinicaltrials |
Data updated 23 days agoSource updated May 7, 2025source: clinicaltrials